COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

An Infectious cDNA Clone of SARS-CoV-2

(2020) Xuping Xie et al.   Cell Host & Microbe

Immunology of COVID-19: current state of the science

(2020) Nicolas Vabret et al.   IMMUNITY

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

(2020) Mark J. Mulligan et al.   NATURE

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

(2020) Ugur Sahin et al.   NATURE

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

(2020) Xiangyang Chi et al.   SCIENCE

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

(2020) Philip J. M. Brouwer et al.   SCIENCE

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

(2020) Antonio E. Muruato et al.   Nature Communications

Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques

(2019) Norbert Pardi et al.   Molecular Therapy-Nucleic Acids

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

(2019) Fatma Doener et al.   VACCINE

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

(2019) Robert A. Feldman et al.   VACCINE

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

(2018) Norbert Pardi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

(2018) Norbert Pardi et al.   Nature Communications

New Vaccine Technologies to Combat Outbreak Situations

(2018) Susanne Rauch et al.   Frontiers in Immunology

Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening

(2018) Alexandra G. Orlandini von Niessen et al.   MOLECULAR THERAPY

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

(2017) Norbert Pardi et al.   NATURE

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection

(2016) Oi-Wing Ng et al.   VACCINE

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection

(2016) Wanbo Tai et al.   VIROLOGY

Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes

(2015) Norbert Pardi et al.   JOURNAL OF CONTROLLED RELEASE

mRNA-based therapeutics — developing a new class of drugs

(2014) Ugur Sahin et al.   NATURE REVIEWS DRUG DISCOVERY

Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies

(2013) Eric Destexhe et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response

(2012) David N. Taylor et al.   VACCINE

Response definition criteria for ELISPOT assays revisited

(2010) Z. Moodie et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Selective CD4+ T Cell Help for Antibody Responses to a Large Viral Pathogen: Deterministic Linkage of Specificities

(2008) Alessandro Sette et al.   IMMUNITY

Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability

(2008) Katalin Karikó et al.   MOLECULAR THERAPY